Verde Servicos Internacionais S.A. reduced its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 12.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 8,922 shares of the biopharmaceutical company’s stock after selling 1,315 shares during the period. Verde Servicos Internacionais S.A.’s holdings in FibroGen were worth $558,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of FGEN. PointState Capital LP bought a new stake in shares of FibroGen during the 1st quarter worth approximately $19,492,000. Artal Group S.A. bought a new stake in shares of FibroGen during the 1st quarter worth approximately $11,550,000. BlackRock Inc. lifted its stake in shares of FibroGen by 4.0% during the 4th quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock worth $299,855,000 after acquiring an additional 244,617 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of FibroGen by 87.3% during the 4th quarter. Deutsche Bank AG now owns 373,555 shares of the biopharmaceutical company’s stock worth $17,704,000 after acquiring an additional 174,126 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of FibroGen by 6,046.8% during the 1st quarter. UBS Group AG now owns 170,943 shares of the biopharmaceutical company’s stock worth $7,897,000 after acquiring an additional 168,162 shares during the last quarter. 63.07% of the stock is owned by hedge funds and other institutional investors.
Get FibroGen alerts:A number of equities research analysts recently issued reports on FGEN shares. Zacks Investment Research lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, May 14th. Mizuho reissued a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, March 29th. BidaskClub raised FibroGen from a “hold” rating to a “buy” rating in a research note on Thursday, May 24th. Finally, ValuEngine raised FibroGen from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $68.83.
In other FibroGen news, Director Jorma Routti sold 6,000 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was sold at an average price of $46.59, for a total transaction of $279,540.00. Following the transaction, the director now directly owns 133,840 shares in the company, valued at approximately $6,235,605.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Pat Cotroneo sold 14,987 shares of the firm’s stock in a transaction on Monday, May 21st. The stock was sold at an average price of $55.04, for a total value of $824,884.48. The disclosure for this sale can be found here. Insiders have sold a total of 272,182 shares of company stock worth $14,513,406 over the last 90 days. 8.96% of the stock is currently owned by company insiders.
FibroGen opened at $63.45 on Friday, according to Marketbeat. FibroGen Inc has a 52 week low of $32.20 and a 52 week high of $65.75. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.61 and a current ratio of 8.61.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. The company had revenue of $31.90 million for the quarter, compared to the consensus estimate of $29.07 million. FibroGen had a negative return on equity of 27.70% and a negative net margin of 102.86%. FibroGen’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the business posted ($0.48) EPS. sell-side analysts expect that FibroGen Inc will post -1.58 earnings per share for the current year.
About FibroGen
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
No comments:
Post a Comment